Pediatric Primary Care Case Studies (160 page)

case presentation for,
441
–444,
446
,
448
,
451

diagnosis of,
441
–448

CDC Five Ps,
442
–443,
443
b

chlamydia trachomatis,
446
–447

diagnostic testing,
444
–448

gonorrhea,
447

HIV,
448

physical examination,
444
–446

sexual history-taking,
441
–444,
443
b

STD risk factors,
445
b

syphilis,
447

epidemiology/etiology of,
446

fundamental contexts of,
441
–452

management of,
449
–452

contraceptive need,
448
–451

counseling,
449
–451

follow-up visits,
452

STI medications,
451
–452,
452
b

objectives for,
441

resources for,
453
–454

Vanderbilt assessment,
180
–181

Vantin.
See
cefpodoxime (Vantin)

Vaseline,
460

vasoconstrictors/antihistamines,
343
t

VCUG (voiding cystourethrogram),
422

venlafaxine (Effexor),
218

vesicoureteral reflux.
See
VUR (vesicoureteral reflux)

ViaSpan,
409

violence risks,
223
,
227
–228

voiding cystourethrogram.
See
VCUG (voiding cystourethrogram)

vomiting/diarrhea,
387
–404

case presentation for,
387
–388,
394
–395,
400

diagnosis of,
392
–397

death risk factors,
391
–392

diagnostic testing,
396
–397

differential,
393
t,
395
–396

history-taking,
391
–395

hospitalization risk factors,
391
–392

telephone consultations,
391
–395

epidemiology/etiology of,
388
–395

acute
vs
. chronic diarrhea,
391
–392

causative agents,
388
–389

CNDC,
391
–392

pathophysiology,
389
–390

fundamental contexts of,
387
,
400
–401

gastroenteritis,
397
–401

management of,
397
–400

feeding resumption,
397
–399

follow-up visits,
399
–400

hydration/rehydration,
397
,
398
t

medications,
399

objectives for,
387

resources for,
401
–402

VUR (vesicoureteral reflux),
418
,
422
–423

W

warfarin toxicity,
306
,
308

WBC (white blood cell) counts,
500

weight-related concerns

breastfeeding/slow weight gain (infants),
103
–114

high blood sugar/overweight,
267
–290

overweight (preschoolers),
85
–102

well-child care

infants,
75
–84

AAP initial visit recommendations,
75

Bright Futures
guidelines for,
79
–80

case presentation for,
76
–79,
81
–82

diagnosis of,
78
–82

follow-up visits for,
80
–81

fundamental contexts of,
75
–76,
82

military family needs and,
81
–82

newborn jaundice,
77
–82

objectives for,
75
–76

resources for,
83

late-preterm infants,
493
–506

case presentation for,
493
,
496
–501,
504

diagnosis of,
496
–501

epidemiology/etiology of,
494
–496

fundamental contexts for,
493
,
505

hyperbilirubinemia,
494
–495

immunizations,
503
–504

jaundice,
494
–495

lung function,
494

management of,
501
–504

metabolic function,
495

objectives for,
493

resources for,
505
–506

sepsis,
494

temperature regulation,
495

Wellbutrin.
See
bupropion (Wellbutrin)

wheezing,
251
–266

case presentation for,
251
–252,
259
–260,
263

diagnosis of,
252
–253,
259
–260

diagnostic testing,
259

EPR-3 guidelines,
259
–260

history-taking,
252
–253

NAEPP (National Asthma Education and Prevention Program) guidelines,
259
–260,
261
t–263t

NHLBI guidelines,
259
–260

physical examinations,
252
–253,
259

severity classification,
259
–260

epidemiology/etiology of,
252
–259

AAP tobacco smoke policy statement,
255

asthma,
253
–257

Asthma and Allergy Foundation cost data,
254

causal factors,
257
,
257
t

CDC data,
253
–255